TrialJournal for immunotherapy of cancer2025

Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria.

Lixing Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.